Last week, I wrote about the billionaire Patrick Soon-Shiong becoming the Elon Musk of biotech. And true to form, we saw his impact on the market after Monday’s announcement that a subsidiary of his NantWorks company was partnering with Sorrento Therapeutics (Nasdaq: SRNE) to develop cancer and autoimmune drugs.
As soon as the news of this partnership hit the streets, Sorrento’s stock price soared more than 80%, closing at $8.48 on Thursday.
Patrick Soon-Shiong, currently worth $13.1 billion, has been methodically adding companies aiming for eradicating cancer through high-tech methodology. Once united, this family network of companies will bring together a variety of specialties: advanced semi-conductor technology, supercomputing, advanced networks and augmented intelligence to diagnose and treat cancer patients with efficiency and speed.
Soon-Shiong’s company will buy a 19.9% equity stake of Sorrento at $5.80 (closing price Friday before deal was announced), adding up to a total investment of 7,188,061 shares for $41,690,754. Patrick’s company also has a three-year warrant to purchase an additional 1,724,138 shares at $5.80 apiece.
The joint venture comprises a $20 million investment and the development of a product called immunotherapy antibody IV.
Shortly after locking up the deal, Soon-Shiong issued a statement: “Combining NantWorks’ cutting edge expertise in genomic and molecular profiling of cancer patients and Sorrento’s industry-leading G-MAB antibody technology, we believe will enable us to develop multiple novel therapies for malignant disorders where there is currently a significant unmet need.”
The announcement caused the social media chatter surrounding Sorrento to increase more than 1,000% giving this stock a lot of rapid momentum. There were also some early warning indicators, such as upticks in the volume of social media chatter messages, before the deal was even completed.
This can be seen in the chart below overlaying social media chatter volume (blue bars) over Sorrento’s stock price.
I’m currently tracking trends surrounding Patrick Soon-Shiong’s efforts and utilizing my Social Media Collective Intelligence system and providing alerts in my Biotech Intel Trader service.
As always, I will continue to monitor the market’s social media collective intelligence and keep you updated on the latest trends.